Hello. At which development phase of your drug are you? When do you plan commercialization? Thank you.

Hello Lea and thank you for your question. We are in the "Preclinical" stage of development. Our objective is to advance Corvida™'s development through Phase 1 and Phase 2 human trials, which will take 4-5 years. At this point we plan to sell or license Corvida™ to a large pharmaceutical company. They will conduct the Phase 3 trials and commercialize the product, which may take an additional 3 - 5 years.

Dear team of Corvidane, kindly let me know if the money raised so far from different sources will be enough to complete the preclinical phase? In addition, I would like to ask if you are going to pursue more crowdfunding or other sources to initiate and complete the clinical t...

Alexandros: My sincere apology for the late response and thank you for your question. Our target to complete the PreClinical phase is $2.5M USD. We are actively pursuing other funding sources including Venture capital on non-dilutive sources such as grants and subsidies to complete the preclinical phase and Phase 1 studies. Let me know if you have any other questions. Damion.

Any updates since the last raise?

Tal, I hope you are well. Your timing is great as Paresh will be sending an update within the next week. We look forward to sharing the update and some new developments with you and our investor community! Damion.

Corvidane Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

1

CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.

2

Corvidane raised $360k from over 200 Investors in previous RegCF.

3

Corvidane granted ~$700k in non-dilutive grants for Research and Development.

4

Results of Corvida™'s effect on LDLr-/- mouse and genes associated with atherosclerosis due in 2023.

5

Corvida™ is protected by patents in the US, Japan and Brazil and are owned by the company.

6

Funds raised will lead to PreIND meetings with the FDA to ensure acceptability of human trials.

7

Corvida™'s components are designated GRAS (Generally Regarded as Safe) by the FDA.

8

This is an opportunity to impact global health and potentially realize significant financial gains.

Corvidane

Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants.

$366,884

Highlights

Team

Memo

Corvidane

Quick facts

Team profiles

Featured investor profiles

$366,884

Highlights

Related company links

Team

Memo